CE Disclosures and Faculty Information

• TARGET AUDIENCE
  
  This activity has been designed to meet the educational needs of medical oncologists, hematologists and hematology-oncology fellows.
  
  OVERVIEW OF ACTIVITY
  
  Each year countless data sets related to the management of common cancers are released to the oncology community via presentation at cancer conferences and publication in peer-reviewed journals. This massive outpouring of information has enormous positive benefits for the cancer community, but the truth is it also creates a major challenge for practicing oncologists and hematologists. To bridge the gap between research and patient care, this web-based activity uses a mix of didactic presentations and moderated case-based discussion to apply evidence-based concepts in routine clinical care. The activity focuses on 7 different areas of oncology: breast cancer, non-small cell lung cancer, genitourinary cancers, non-Hodgkin and Hodgkin lymphomas, multiple myeloma, gastrointestinal cancers and ovarian cancer. These have been selected based on a number of factors, including the overwhelming need for and interest of practicing oncologists in additional educational resources in these areas. By providing access to the latest research developments across these cancers, this activity will assist medical oncologists, hematologists and hematology-oncology fellows in the formulation of up-to-date clinical management strategies.
  
  LEARNING OBJECTIVES

  • Effectively apply the results of practice-changing clinical research to the care of patients with breast, lung, genitourinary, gastrointestinal, ovarian and hematologic cancers.
  • Compare and contrast the clinical relevance of recent pivotal cancer research results as published in peer-reviewed journals and/or presented at major oncology conferences.
  • Recall ongoing trials in breast, lung, genitourinary, gastrointestinal, ovarian and hematologic cancers, and counsel/refer appropriately selected patients for study participation.
  • Utilize an understanding of tumor biomarkers and single and multigene signatures to individualize the care of patients with cancer.
  • Educate patients with diverse hematologic cancers and solid tumor types about the benefits and risks of new therapeutic agents and strategies.
  • Employ case-based learning to refine or validate existing cancer-specific treatment algorithms.

  ACCREDITATION STATEMENT
  
  Research To Practice is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.
  
  CME credit is no longer available for this issue
  
  CREDIT DESIGNATION STATEMENT
  
  CME credit is no longer available for this issue
  
  HOW TO USE THIS CME ACTIVITY
  
  This CME activity consists of a video component. The participant should watch the video.
  
  CME credit is no longer available for this issue
  
  CONTENT VALIDATION AND DISCLOSURES
  
  Research To Practice (RTP) is committed to providing its participants with high-quality, unbiased and state-of-the-art education. We assess potential conflicts of interest with faculty, planners and managers of CME activities. Real or apparent conflicts of interest are identified and resolved through a conflict of interest resolution process. In addition, all activity content is reviewed by both a member of the RTP scientific staff and an external, independent physician reviewer for fair balance, scientific objectivity of studies referenced and patient care recommendations.
  
  FACULTY — The following faculty (and their spouses/partners) reported real or apparent conflicts of interest, which have been resolved through a conflict of interest resolution process:
  
  Kenneth C Anderson, MD
  Kraft Family Professor of Medicine
  Harvard Medical School
  Chief, Division of Hematologic Neoplasia
  Director, Jerome Lipper Multiple Myeloma Center
  Director, LeBow Institute for Myeloma Therapeutics
  Dana-Farber Cancer Institute
  Boston, Massachusetts
  
  Advisory Committee: Bristol-Myers Squibb Company, Celgene Corporation, Merck and Company Inc, Millennium: The Takeda Oncology Company, Novartis Pharmaceuticals Corporation, Onyx Pharmaceuticals Inc.
  
  John Heymach, MD, PhD
  Associate Professor of Thoracic/Head and Neck Medical Oncology
  The University of Texas MD Anderson Cancer Center
  Houston, Texas
  
  Consulting Agreements: AstraZeneca Pharmaceuticals LP, Boehringer Ingelheim Pharmaceuticals Inc, Genentech BioOncology, GlaxoSmithKline, Pfizer Inc; Paid Research: AstraZeneca Pharmaceuticals LP, GlaxoSmithKline, Pfizer Inc.
  
  Craig Moskowitz, MD
  Clinical Director, Division of Hematologic Oncology
  Member, Lymphoma Service
  Memorial Sloan-Kettering Cancer Center
  New York, New York
  
  Advisory Committee: Cephalon Inc, Genentech BioOncology, Seattle Genetics; Paid Research: Cephalon Inc, Genentech BioOncology, Lilly USA LLC, Plexxikon Inc, Seattle Genetics.
  
  William K Oh, MD
  Chief, Division of Hematology and Medical Oncology
  Professor of Medicine and Urology
  Ezra M Greenspan, MD Professor in Clinical Cancer Therapeutics
  Mount Sinai School of Medicine
  Associate Director of Clinical Research
  The Tisch Cancer Institute
  New York, New York
  
  Advisory Committee: Sanofi; Consulting Agreements: Dendreon Corporation, Pfizer Inc.
  
  Eileen M O'Reilly, MD
  Associate Attending
  GI Medical Oncology Service
  Memorial Sloan-Kettering Cancer Center
  Associate Professor of Medicine
  Weill Medical College of Cornell University
  New York, New York
  
  Consulting Agreements: Bayer HealthCare Pharmaceuticals, Bristol-Myers Squibb Company, Celsion Corporation, Chugai Pharmaceutical Co Ltd, Clovis Oncology, Enzon Pharmaceuticals, Genentech BioOncology, ImClone Systems, a wholly owned subsidiary of Eli Lilly and Company, Jennerex Inc, MediGene Inc, Merck and Company Inc, Novartis Pharmaceuticals Corporation, OSI Oncology, Piramal Healthcare Limited, Polaris Group, Proacta Inc, Roche Laboratories Inc, Sanofi, Vicus Therapeutics, ZIOPHARM Oncology Inc; Paid Research: Amgen Inc, Astellas, AstraZeneca Pharmaceuticals LP, Bayer HealthCare Pharmaceuticals, Chugai Pharmaceutical Co Ltd, Clovis Oncology, ImClone Systems, a wholly owned subsidiary of Eli Lilly and Company, MediGene Inc, Roche Laboratories Inc.
  
  Joyce O’Shaughnessy, MD
  Co-Director, Breast Cancer Research Program
  Baylor-Charles A Sammons Cancer Center
  Texas Oncology, PA
  US Oncology
  Dallas, Texas
  
  Advisory Committee: Biogen Idec, Bristol-Myers Squibb Company, Caris Diagnostics Inc, Eisai Inc, Genentech BioOncology, GlaxoSmithKline, GTx Inc, Johnson & Johnson Pharmaceuticals, Roche Laboratories Inc, Sanofi; Speakers Bureau: Bristol-Myers Squibb Company, Celgene Corporation, Sanofi.
  
  David R Spriggs, MD
  Head, Division of Solid Tumor Oncology
  Winthrop Rockefeller Chair of Medical Oncology
  Memorial Sloan-Kettering Cancer Center
  New York, New York
  
  Advisory Committee: AstraZeneca Pharmaceuticals LP, Johnson & Johnson Pharmaceuticals, Lilly USA LLC, ZIOPHARM Oncology Inc.
  
  MODERATOR — Dr Love is president and CEO of Research To Practice, which receives funds in the form of educational grants to develop CME activities from the following commercial interests: Abbott Laboratories, Allos Therapeutics, Amgen Inc, ArQule Inc, Astellas, Bayer HealthCare Pharmaceuticals/Onyx Pharmaceuticals Inc, Biodesix Inc, Biogen Idec, Boehringer Ingelheim Pharmaceuticals Inc, Bristol-Myers Squibb Company, Celgene Corporation, Cephalon Inc, Daiichi Sankyo Inc, Dendreon Corporation, Eisai Inc, EMD Serono Inc, Genentech BioOncology, Genomic Health Inc, ImClone Systems, a wholly owned subsidiary of Eli Lilly and Company, Incyte Corporation, Lilly USA LLC, Medivation Inc, Millennium: The Takeda Oncology Company, Mundipharma International Limited, Novartis Pharmaceuticals Corporation, Regeneron Pharmaceuticals, Sanofi, Seattle Genetics, Spectrum Pharmaceuticals Inc and Teva Pharmaceuticals.
  
  RESEARCH TO PRACTICE STAFF AND EXTERNAL REVIEWERS — The scientific staff and reviewers for Research To Practice have no real or apparent conflicts of interest to disclose.
  
  This educational activity contains discussion of published and/or investigational uses of agents that are not indicated by the Food and Drug Administration. Research To Practice does not recommend the use of any agent outside of the labeled indications. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications and warnings. The opinions expressed are those of the presenters and are not to be construed as those of the publisher or grantors.
  
  This activity is supported by educational grants from Astellas/Medivation Inc, Celgene Corporation, Cephalon Inc, Eisai Inc, Genentech BioOncology, Genomic Health Inc, Lilly USA LLC, Novartis Pharmaceuticals Corporation and Sanofi.
  
  Hardware/Software Requirements:
  An Internet connection that is at least 28.8 Kbps
  A monitor set to 1280 x 1024 pixels or more
  Netscape 7.x or newer, Internet Explorer 5.x or newer, or Firefox
  Macromedia Flash plug-in 6.0 or greater
  Adobe Acrobat Reader
  (Optional) Sound card and speakers for audio
  
  Last review date: February 2012
  Expiration date: February 2013